If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV
50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How is Reyvow® (lasmiditan) absorbed and distributed?
Reyvow (lasmiditan) is rapidly absorbed after oral administration. In patients with migraine, absorption or pharmacokinetics of lasmiditan was similar during a migraine attack or during the interictal period.
Following oral administration, lasmiditan is rapidly absorbed with a median Tmax of 1.8 hours.1
In patients with migraine, the absorption or pharmacokinetics of lasmiditan was not different during a migraine attack versus during the interictal period.1
The oral bioavailability over the clinical dose range of 50 mg to 200 mg is predicted to be 50% to 58%, based on the results from a population pharmacokinetics analysis.2
Effect of Food on Absorption
Lasmiditan may be taken with or without food as administration with meals was not associated with a clinically relevant effect on exposure to lasmiditan.1
Coadministration of lasmiditan with a high-fat meal
- increased mean lasmiditan Cmax and AUC values by 22% and 19%, respectively, and
- delayed the median Tmax by 1 hour.1
The human plasma protein binding of lasmiditan is
- approximately 55% to 60%, and
- independent of concentration between 15 and 500 ng/mL.1
Enclosed Prescribing Information
1Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
AUC = area under the curve
Cmax = maximum observed drug concentration
Tmax = time of maximum observed drug concentration
Date of Last Review: August 10, 2021